Shaped Forms Adapted For Noningestible Use Other Than Suppository Type (e.g., Films, Inserts, Etc.) Patents (Class 514/953)
  • Patent number: 6120790
    Abstract: Purpose: the purpose of the present invention is to offer resin compositions which have antimicrobial/fungistatic properties which show outstanding dispersion and outstandingly durable performance. Constitution: thermoplastic resin compositions characterized in that an antimicrobial/fungistatic agent, and particularly an inorganic antimicrobial/fungistatic agent, is compounded with a copolymer containing a polyether chain as a constituent unit, such as a polyether/polyamide copolymer, a polyether/polyester copolymer or a polyether urethane, for example, at 0.05-20 wt. %, and thermoplastic resin compositions which comprise a thermoplastic resin, an antimicrobial/fungistatic agent and a copolymer having a polyether chain as a constituent unit.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: September 19, 2000
    Assignee: Elf Atochem S.A.
    Inventors: Takatoshi Kuratsuji, Jerome Maillet, Yoshiyuki Miyaki
  • Patent number: 6074664
    Abstract: An administration form for the release of collagenase to wounds is characterised in that it exhibits a combination of specific properties as hereinbelow:a. it is coherent, flat-shaped and deformable;b. it has a superficial extension that is equal to or smaller than the wound surface to be treated;c. it comprises collagenase in defined amounts in homogeneously distributed form;d. it is designed for the controlled release of collagenase.
    Type: Grant
    Filed: November 17, 1997
    Date of Patent: June 13, 2000
    Assignee: Knoll AG
    Inventors: Michael Roreger, Heinz Einig
  • Patent number: 6066338
    Abstract: In order to prevent conception and/or the spread of sexually transmitted diseases (STD's) one or more lectins capable of binding sperm and/or the pathogenic microorganisms responsible for STD's are administered to the vagina prior to sexual intercourse. The lectins immobilize the sperm to render them incapable of fertilization and also bind to the microorganisms to render them non-pathogenic or to the cells to prevent infection by the microorganisms. Lectins can also be administered to treat sexually transmitted vaginal infections.The invention also encompasses a device for to be placed in the vault of the vagina which comprises a ring which surrounds the cervix and a membrane spanning the central aperture of the ring to prevent the direct contact of ejaculate with the cervical tissues. The device is impregnated or coated with lectins and releases them into the vaginal environment over a period of time.
    Type: Grant
    Filed: June 15, 1998
    Date of Patent: May 23, 2000
    Assignee: Legere Pharmaceuticals, Ltd.
    Inventors: Michael J. Oldham, Bruce F. Rose, Howard C. Krivan
  • Patent number: 6060076
    Abstract: Controlled release devices are shaped and placed in locations through which insects and/or other cold blooded animals generally enter an area or a structure sought to be protected. The controlled release devices include a polymeric matrix and a pesticide contained in the matrix. The pesticide is gradually released out of the matrix to the surface of the device. The pesticide on the surface of the device kills the intruding insects or other cold blooded animals that come in contact with the pesticide. In addition, if the device is in contact with a permeable structure or object, the pesticide released onto the surface of the device is absorbed by such permeable structure or object to provide a barrier to entry by the insects and/or other cold blooded animals.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 9, 2000
    Assignee: Battelle Memorial Institute
    Inventors: Peter Van Voris, Dominic A. Cataldo
  • Patent number: 6042845
    Abstract: There is disclosed a method for the treatment of fungal diseases in nails, which comprises the topical administration to the nail and, if desired, also to the surrounding skin, of (1) a sulfhydryl containing amino acid or a derivative thereof, the pharmaceutically acceptable salts or esters thereof, or stereoisomers thereof, (2) urea, (1) and (2) being administered in an amount sufficient to enhance the permeation of antifungal drugs through nail tissue, either prior to or, preferably, concurrently with the topical administration to the nail of (3) an effective amount of an antifungal drug.
    Type: Grant
    Filed: September 2, 1997
    Date of Patent: March 28, 2000
    Assignee: Johnson & Johnson Consumer Products, Inc.
    Inventors: Ying Sun, Jue-Chen Liu, Elizabeth S. Kimbleton, Jonas C. T. Wang
  • Patent number: 6013275
    Abstract: Since an inorganic and/or organic antibacterial agent and a hydrophilic substance are used in combination in this invention to produce an antibacterial composition, the intrinsic antibacterial activity of the inorganic or organic antibacterial agent is markedly increased, so that the antibacterial agent used even in a low concentration shows a high antibacterial activity. High antibacterial moldings can be obtained at a relatively low cost by laminating the antibacterial composition of the invention on an inorganic or organic substrate.
    Type: Grant
    Filed: January 8, 1998
    Date of Patent: January 11, 2000
    Assignee: Toyo Boseki Kabushiki Kaisha
    Inventors: Shigeji Konagaya, Hideto Ohashi, Akito Hamano, Masahiro Seko, Masakazu Tanaka
  • Patent number: 5958444
    Abstract: Disclosed are methods for treating vesicoureteral reflux in a mammal wherein a composition comprising a water insoluble biocompatible polymer and a biocompatible solvent is delivered to the subureteral tissue of the mammal.
    Type: Grant
    Filed: June 13, 1997
    Date of Patent: September 28, 1999
    Assignee: Micro Therapeutics, Inc.
    Inventors: George Wallace, Richard J. Greff
  • Patent number: 5955112
    Abstract: A non-stinging styptic composition in the form of a water soluble resin coated cast pencil, for stopping bleeding from cuts and nicks received during shaving. The composition comprises aluminum sulfate, aloe, glycerine, lidocaine and polyethylene glycol 400.
    Type: Grant
    Filed: February 11, 1998
    Date of Patent: September 21, 1999
    Inventor: Jeffrey Kaplan
  • Patent number: 5914295
    Abstract: Implantable, partially biodegradable, polymer-containing molded articles for the administration of active substances to plants are characterized by the fact that they comprise at least one hydrophobic polymer.
    Type: Grant
    Filed: June 11, 1997
    Date of Patent: June 22, 1999
    Assignee: LTS Lohmann Therapie-Systeme GmbH
    Inventors: Hans-Rainer Hoffmann, Malgorzata Kloczko, Michael Roreger
  • Patent number: 5912005
    Abstract: The invention covers a method of implanting a living donor cell into a host animal without inflammatory response or rejection of the donor cell by the host animal, by obtaining an uncoated particle of a biocompatible, temperature-independent gel that encapsulates the living donor cell, wherein the uncoated particle provides a molecular weight cutoff that prevents host animal immune cells from entering the particle, yet does not have to prevent entry of host animal IgG and complement into the particle, and implanting the uncoated particle into the host animal.
    Type: Grant
    Filed: November 19, 1996
    Date of Patent: June 15, 1999
    Assignee: BioHybrid Technologies, Inc.
    Inventors: Robert P. Lanza, Willem M. Kuhtreiber, William L. Chick
  • Patent number: 5874109
    Abstract: Carriers comprising silica-based glass providing for the controlled release of biologically active molecules, their methods of preparation, and methods of use are disclosed. The carriers are prepared using a sol-gel-derived process. Biologically active molecules are incorporated within the matrix of the glass during production.
    Type: Grant
    Filed: September 4, 1997
    Date of Patent: February 23, 1999
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Paul Ducheyne, Shulamith Radin, Erick Manuel Santos
  • Patent number: 5871777
    Abstract: Carriers comprising silica-based glass providing for the controlled release of biologically active molecules, their methods of preparation, and methods of use are disclosed. The carriers are prepared using a sol-gel-derived process. Biologically active molecules are incorporated within the matrix of the glass during production.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: February 16, 1999
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Paul Ducheyne, Shulamith Radin, Erick Manuel Santos
  • Patent number: 5869079
    Abstract: Combinations of hydrophilic and hydrophobic entities in a biodegradable sustained release implant are shown to modulate each other's rate of release. Formulations of a therapeutically active agent and modulator provide controlled, sustained drug release for an extended period of time.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: February 9, 1999
    Assignee: Oculex Pharmaceuticals, Inc.
    Inventors: Vernon Wong, Frank Kochinke
  • Patent number: 5856271
    Abstract: The invention is a method of making a controlled release device that is free of defects. According to one aspect of the present invention, a method has the steps of first combining an active chemical with a dried carrier into a bound friable mixture followed by combining the bound friable mixture with a polymer preform prior to forming a device. According to another aspect of the present invention, a method has the steps of heating and mixing a casting urethane with an active chemical into a first solution, heating and mixing a trialkanolamine with a soft segment cross-linker into a second solution, and mixing the two solutions. A further aspect of the present invention is a composition of a casting urethane.
    Type: Grant
    Filed: August 19, 1996
    Date of Patent: January 5, 1999
    Assignee: Battelle Memorial Institute
    Inventors: Dominic C. Cataldo, Peter Van Voris
  • Patent number: 5853746
    Abstract: Methods and compositions are provided for the treatment and repair of defects in the cartilage or bone of humans and other animals as in full-thickness defects in joints. To induce cartilage formation, a defect in cartilage is filled with a matrix having pores sufficiently large to allow cartilage repair cells to populate the matrix. The matrix contains an anti-angiogenic agent that serves as a functional barrier to prevent vascularization and bone growth into the cartilage area. The matrix filling the defect in cartilage may also contain a proliferation agent and a chemotactic agent, and a transforming factor in an appropriate delivery system. A functional barrier between the bone and cartilage areas of a full-thickness defect may also be created by heat-treating the areas of bleeding to form a transient tissue barrier which prevents blood vessels and associated cells from penetrating from the bone area into the cartilage area.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: December 29, 1998
    Assignee: Robert Francis Shaw
    Inventor: Ernst B. Hunziker
  • Patent number: 5849322
    Abstract: A composition for transmucosally administering a drug to the oral cavity comprises an adhesive layer comprising a hydrophilic polymer having one surface adapted to contact a first tissue of the oral cavity and adhere thereto when wet and an opposing surface in contact with and adhering to an adjacent drug-containing layer comprising an effective amount of a drug and optionally an effective amount of a permeation enhancer, wherein the drug-containing layer is adapted to contact and be in drug transfer relationship with a mucosal tissue of the oral cavity when the adhesive layer contacts and adheres to the first tissue. Preferred drugs include peptides, such as glucagon-like insulinotropic peptides. A method of transmucosally administering a drug to the oral cavity is also disclosed.
    Type: Grant
    Filed: October 23, 1995
    Date of Patent: December 15, 1998
    Assignee: Theratech, Inc.
    Inventors: Charles D. Ebert, Sonia J. Heiber, Mark K. Gutniak
  • Patent number: 5849331
    Abstract: Carriers comprising silica-based glass providing for the controlled release of biologically active molecules, their methods of preparation, and methods of use are disclosed. The carriers are prepared using a sol-gel-derived process. Biologically active molecules are incorporated within the matrix of the glass during production.
    Type: Grant
    Filed: September 3, 1997
    Date of Patent: December 15, 1998
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Paul Ducheyne, Shulamith Radin, Erick Manuel Santos
  • Patent number: 5847010
    Abstract: The present invention is a method of preventing or ameliorating the episodic recurrence of MS, comprising administering an effective amount of selective phosphodiesterase inhibitors of Type IV, e.g., Rolipram, e.g., wherein the severity of the episodic recurrences is ameliorated or the time period between episodes is lengthened.
    Type: Grant
    Filed: September 22, 1997
    Date of Patent: December 8, 1998
    Assignee: Berlex Laboratories, Inc.
    Inventors: Joel Hedgpeth, Helmut Wachtel
  • Patent number: 5837228
    Abstract: A bioerodible controlled release dosage form is disclosed comprising a polymer formed by condensing beneficial agents having a hydroxyl functionality of two or more with diketene acetals or divinyl ethers which delivers beneficial agents to a biological environment of use. A statistically significant portion of the beneficial agent is covalently bonded within the polymer matrix.
    Type: Grant
    Filed: September 2, 1992
    Date of Patent: November 17, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Chung Shih, Gaylen M. Zentner, Randall V. Sparer, R. Lee Seward
  • Patent number: 5780051
    Abstract: The present invention features methods and articles of manufacture for treating nicotine withdrawal symptoms and promoting smoking cessation. The methods and articles feature the administration of an effective amount of a nicotine substitute and monitor the presence of nicotine in the biological sample of such subject with a nicotine detection system.
    Type: Grant
    Filed: January 22, 1997
    Date of Patent: July 14, 1998
    Assignee: DynaGen, Inc.
    Inventors: Amruta R. Eswara, Neal Muni, F. Howard Schneider, Peter J. Mione
  • Patent number: 5766632
    Abstract: In order to prevent conception and/or the spread of sexually transmitted diseases (STD's) one or more lectins capable of binding sperm and/or the pathogenic microorganisms responsible for STD's are administered to the vagina prior to sexual intercourse. The lectins immobilize the sperm to render them incapable of fertilization and also bind to the microorganisms to render them non-pathogenic or to the cells to prevent infection by the microorganisms. Lectins can also be administered to treat sexually transmitted vaginal infections. The invention also encompasses a device for to be placed in the vault of the vagina which comprises a ring which surrounds the cervix and a membrane spanning the central aperture of the ring to prevent the direct contact of ejaculate with the cervical tissues. The device is impregnated or coated with lectins and releases them into the vaginal environment over a period of time.
    Type: Grant
    Filed: February 29, 1996
    Date of Patent: June 16, 1998
    Assignee: Legere Pharmaceuticals, Ltd.
    Inventors: Michael J. Oldham, Bruce F. Rose
  • Patent number: 5756127
    Abstract: A bioresorbable string of implantable beads in which the beads consist essentially of calcium sulfate and a quantity of a drug suitable for treating tissue disorders, and in which both the beads and the line that joins the beads together are bioresorbable.
    Type: Grant
    Filed: October 29, 1996
    Date of Patent: May 26, 1998
    Assignee: Wright Medical Technology, Inc.
    Inventors: Bernard F. Grisoni, Steve Gitelis, Timothy L. Harrison, Jack E. Parr, Ben R. Shappley
  • Patent number: 5736132
    Abstract: A formulated biological adhesive composition utilizes tissue transglutaminase in a pharmaceutically acceptable aqueous carrier. The tissue transglutaminase is used in an effective catalytic amount to promote adhesion between tissue surfaces upon treatment thereof by catalyzing the reaction between glutaminyl residues and amine donors of the tissue and/or the enzyme. The carrier contains a divalent metal ion such as calcium to promote said reaction.
    Type: Grant
    Filed: January 29, 1996
    Date of Patent: April 7, 1998
    Assignee: Orthogene, Inc.
    Inventors: Kay Juergensen, Daniel Aeschlimann, Ernst B. Hunziker
  • Patent number: 5707645
    Abstract: A small, reusable, previously cooled or frozen bladder that is applied to the anal area of a user. The bladder consists of two two-ply sheets of a flexible, semi-porous material, such as polyethylene, hermetically heat sealed together at the edges to form an internal cavity. The cavity contains a cold-temperature storage means, such as water, glycerol, a combination thereof, or other chemical slurry, and a medicinal agent, such as witchhazel, shark oil, yarrow, other astringents, and lidocaine or other pain relievers.
    Type: Grant
    Filed: September 10, 1996
    Date of Patent: January 13, 1998
    Inventor: Mark Wierson
  • Patent number: 5702721
    Abstract: A transdermal therapeutic system exhibiting layered structure consists of a backing layer which is impermeable to active substances, a matrix having water-insoluble basic material and islands (inclusions) divided therein, and a layer controlling the access of cutaneous liquid by means of which the matrix is activatable. Process for the production are described.
    Type: Grant
    Filed: August 30, 1994
    Date of Patent: December 30, 1997
    Assignee: LTS Lohmann Therapie-Systeme GmbH & Co. KG
    Inventors: Michael Horstmann, Fritz Herrmann
  • Patent number: 5696164
    Abstract: There is disclosed a method for the treatment of fungal diseases in nails, which comprises the topical administration to the nail and, if desired, also to the surrounding skin, of (1) a sulfhydryl containing amino acid or a derivative thereof, the pharmaceutically acceptable salts or esters thereof, or stereoisomers thereof, (2) urea, (1) and (2) being administered in an amount sufficient to enhance the permeation of antifungal drugs through nail tissue, either prior to or, preferably, concurrently with the topical administration to the nail of (3) an effective amount of an antifungal drug.
    Type: Grant
    Filed: December 22, 1994
    Date of Patent: December 9, 1997
    Assignee: Johnson & Johnson Consumer Products, Inc.
    Inventors: Ying Sun, Jue-Chen Liu, Elizabeth S. Kimbleton, Jonas C. T. Wang
  • Patent number: 5686094
    Abstract: A polymeric delivery system which is formed by a polycarbophil type composition with an active agent, optionally in the presence of water and/or other cosolvent. The resulting product is especially useful as a carrier or coating of active compositions, such as pharmaceuticals and the like. The composition is also useful for the controlled or sustained release of active agents that are drugs, cosmetic agents, household agents, agricultural agents, industrial chemical agents and nutritional agents. A composition and method for the treatment of xerostomia is also disclosed, comprising polycarbophil in the form of an article having a shape suitable for insertion into the mouth.
    Type: Grant
    Filed: April 1, 1991
    Date of Patent: November 11, 1997
    Assignee: Theratech, Inc.
    Inventor: Ramesh N. Acharya
  • Patent number: 5665378
    Abstract: The present invention relates to a transdermal therapeutic formulation comprising capsaicin, a nonsteroidal anti-inflammatant and pamabrom. The formulation is used to alleviate pain or discomfort in a mammal by being applied to the skin of the mammal thereby causing the active ingredients in the formulation to pass into and/or through the skin of the mammal. In a preferred embodiment of the present invention, the formulation is used in patch form for the treatment of the pain and discomfort associated with menstrual cramps, water retention (e.g., "bloating") and/or muscular pain (e.g., muscular back pain).
    Type: Grant
    Filed: November 21, 1995
    Date of Patent: September 9, 1997
    Inventors: Roosevelt Davis, Susan A. Primo-Davis
  • Patent number: 5662935
    Abstract: An improved process for preparing controlled release pharmaceutical forms comprises exposing a mixture comprising one or more excipients and one or more active ingredients compatible with each other and with said excipients to mechanical or electromechanical actions for a well established time and within a wide range of frequencies to give tablets, matrices or mono or multilayered films. Said forms can be optionally crushed to give a granulate or powder. Depending on the employed excipient, a delayed or rapid but always controllable release of the active ingredient can be attained.
    Type: Grant
    Filed: June 23, 1995
    Date of Patent: September 2, 1997
    Assignee: Saitec S.R.L.
    Inventor: Giuseppe Motta
  • Patent number: 5651980
    Abstract: The invention covers a method of implanting a living donor cell into a host animal without inflammatory response or rejection of the donor cell by the host animal, by obtaining an uncoated particle of a biocompatible, temperature-independent gel that encapsulates the living donor cell, wherein the uncoated particle provides a molecular weight cutoff that prevents host animal immune cells from entering the particle, yet does not have to prevent entry of host animal IgG and complement into the particle, and implanting the uncoated particle into the host animal.
    Type: Grant
    Filed: April 15, 1994
    Date of Patent: July 29, 1997
    Assignee: Biohybrid Technologies, Inc.
    Inventors: Robert P. Lanza, Willem M. Kuhtreiber, William L. Chick
  • Patent number: 5651973
    Abstract: The progesterone analog ST1435 has now been found to attain therapeutically effective levels upon topical application to the skin. ST1435 can be administered topically either in liquid or semisolid base such as a cream or gel or in a solid base such as a transdermal device such as a disk, band patch or bracelet. The invention further provides topical applications suitable for transdermal delivery of therapeutically effective amounts of ST1435.
    Type: Grant
    Filed: November 30, 1992
    Date of Patent: July 29, 1997
    Assignee: The Population Council
    Inventors: Alfred Moo-Young, Ana Zepeda-Ortega, Horacio Bruno Croxatto
  • Patent number: 5648390
    Abstract: A method has been discovered for repelling ants by treating objects or areas with effective amounts of compositions that include (a) one or more C.sub.6 to C.sub.8 carboxylic acids; (b) one or more C.sub.6 to C.sub.14 alcohols; (c) one or more esters which are reaction products of (a) and (b) or an ester which is a reaction product of the repellents and other carboxylic acids or alcohols; (d) one or more C.sub.6 to C.sub.11 carboxylic acid esters; (e) one or more C.sub.6 to C.sub.14 ketones; or (f) mixtures thereof.
    Type: Grant
    Filed: August 4, 1994
    Date of Patent: July 15, 1997
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Robert K. Vander Meer, William A. Banks, Clifford S. Lofgren
  • Patent number: 5580569
    Abstract: An article for tissue-specific delivery of therapeutic agents constitutes a substrate of a material that is biodegradable in situ in human tissue, which substrate is configured into a projectile and proportioned for insertion into a channel of an endoscope, the substrate having incorporated thereinto selectable therapeutic agents to be delivered, the projectile including, upon an exterior surface, a capacity for tissue affixation to the tissue of interest.
    Type: Grant
    Filed: November 4, 1993
    Date of Patent: December 3, 1996
    Inventor: Vincent C. Giampapa
  • Patent number: 5565210
    Abstract: Heteromorphic sponges are described which have matrix structures with oriented substructures added to facilitate cellular invasion. A sponge may be used as a wound implant by cutting it to the shape of a wound bed and placing therein. The matrix structure provides conduits which assist invasion of the sponge by cells which degrade the sponge and lay down new tissue to replace it. The incorporation of active agents in the matrix and/or substructures enhances wound healing.
    Type: Grant
    Filed: April 5, 1995
    Date of Patent: October 15, 1996
    Assignee: Johnson & Johnson Medical, Inc.
    Inventors: Arthur L. Rosenthal, Nicholas D. Light, Paul W. Watt
  • Patent number: 5543148
    Abstract: The invention presented relates to a stick delivery system for the topical application of a treatment agent. The inventive stick delivery system includes a solvent such as a polyhydric alcohol; a gelling agent which can be an alkali metal stearate, an alkali metal palmitate or mixtures thereof; and a treatment agent selected from the group consisting of an anesthetic, an antihistamine, an anti-inflammatory agent, an antifungal agent, or mixtures thereof.
    Type: Grant
    Filed: July 12, 1994
    Date of Patent: August 6, 1996
    Assignee: Combe, Incorporated
    Inventor: Herbert Lapidus
  • Patent number: 5536503
    Abstract: A drug delivery system useful in aiding individuals in the cessation of smoking or chewing nicotine containing products is described. The delivery system includes a physical constraint modulation system (PCMS.TM.) containing lobeline. The drug delivery system is capable of delivering lobeline to an individual in a controlled, sustained release manner and providing long-term therapeutic levels of lobeline to the individual. The delivery of lobeline in such a manner reduces or eliminates the individual's smoking or chewing habit. The PCMS may be a biodegradable polymer containing the lobeline capable of subcutaneous or intramuscular injection or implantation into the individual or may be part of a transdermal patch containing lobeline. Also described are methods of using the drug delivery systems and kits containing the drug delivery systems.
    Type: Grant
    Filed: April 3, 1995
    Date of Patent: July 16, 1996
    Assignee: DynaGen, Inc.
    Inventors: Judith P. Kitchell, Indu A. Muni, Yvonne N. Boyer
  • Patent number: 5529782
    Abstract: A dissolvable element containing an agent material is used for local administration of the agent material in an internal body area. The dissolvable element is made of dissolvable polymer material and/or complex carbohydrate material which are food grade materials and have selected dissolving properties, such that it remains in substantially solid form before use, and dissolves due to human body temperatures and moisture during use to release the agent material in a desired timed release and dosage. As a contraceptive, the dissolvable element is preferably a film made of polyvinyl alcohol, polyethylene oxide, hydroxypropyl methyl cellulose and/or carboxymethyl cellulose. The dissolvable element may be formed as a laminate of different film layers for compound release properties, or it may be ground into particles and incorporated in a tampon or suppository. The dissolvable element may be foamed as a means for increasing its dissolution rate.
    Type: Grant
    Filed: November 3, 1994
    Date of Patent: June 25, 1996
    Inventor: Robert Staab
  • Patent number: 5520924
    Abstract: The present invention features methods and articles of manufacture for delivering drug to the oral cavity. The methods and articles feature drug held in a polyvinyl alcohol matrix. The matrix releases the drug in a sustained constant manner.
    Type: Grant
    Filed: July 9, 1993
    Date of Patent: May 28, 1996
    Assignee: Mizu Systems Corporation
    Inventors: Robert J. Chapman, Charles M. Habib
  • Patent number: 5516523
    Abstract: A method and system for mucosally administering a macromolecular drug to mucosa of the oral cavity is shown. The system comprises an inner drug/enhancer/polymer layer having one surface adapted to contact and adhere to the mucosal tissue of the oral cavity and an opposing surface in contact with and adhering to an overlying inert layer. The inner layer contains from about two to sixty percent by weight of a bile salt enhancer, five to sixty five percent by weight of a hydrophilic polymer which is water soluble or swellable and an effective amount of a macromolecular drug having a molecular weight of at least 500 daltons. Polysaccharides, polypeptides and proteins are preferred forms of macromolecular drugs. The bile salt enhancer facilitates the delivery of macromolecules such as low molecular weight heparin and calcitonin. The polymer serves as a plasticizer to prevent the crystallization and/or aggregation of such macromolecular drugs. Hydroxypropyl cellulose is a particularly suitable polymer.
    Type: Grant
    Filed: May 16, 1994
    Date of Patent: May 14, 1996
    Assignee: TheraTech, Inc.
    Inventors: Sonia J. Heiber, Charles D. Ebert, Sirish C. Dave
  • Patent number: 5508263
    Abstract: The present invention provides osteogenically active protein preparations comprising a heterodimer of P3 OF 31-34 subunit B and P3 OF 31-34 subunit D, which subunits are linked with at least one disulfide bond and methods for their preparation. The invention further provides cell lines transformed with nucleotide sequences encoding P3 OF 31-34 subunit B and P3 OF 31-34 subunit D and vectors comprising those sequences in operative association with an expression control sequence.
    Type: Grant
    Filed: August 29, 1994
    Date of Patent: April 16, 1996
    Assignee: Xoma Corporation
    Inventors: Lynn Grinna, Georgia Theofan, Thomas F. Parsons
  • Patent number: 5496559
    Abstract: A solid formulation for buccal or oral administration which contains a proteinaceous physiologically active substance as an active ingredient, as well as collagen and a water-soluble additive, said formulation being characterized by being porous and having a good disintegration property, and a preparation thereof are provided.
    Type: Grant
    Filed: September 30, 1993
    Date of Patent: March 5, 1996
    Assignee: Sumitomo Pharmaceuticals Company, Limited
    Inventors: Keiji Fujioka, Shigeji Sato, Yoshihiro Takada
  • Patent number: 5486362
    Abstract: A drug delivery system useful in treating an individual for a drug dependence is described. One embodiment of the system is useful for aiding individuals in the cessation of smoking or chewing nicotine containing products is described. The delivery system includes a physical constraint modulation system (PCMS.TM.) containing lobeline. The drug delivery system is capable of delivering lobeline to an individual in a controlled, sustained release manner and providing long-term therapeutic levels of lobeline to the individual. The delivery of lobeline in such a manner reduces or eliminates the individual's smoking or chewing habit. The PCMS may be a biodegradable polymer containing the lobeline capable of subcutaneous or intramuscular injection or implantation into the individual or may be part of a transdermal patch containing lobeline. Also described are methods of using the drug delivery systems in treating other drug dependencies and kits containing the drug delivery systems.
    Type: Grant
    Filed: October 21, 1993
    Date of Patent: January 23, 1996
    Assignee: DynaGen, Inc.
    Inventors: Judith P. Kitchell, Indu A. Muni, Yvonne N. Boyer
  • Patent number: 5482932
    Abstract: The invention provides alginate gels which have the form of a fibrous paste and which particularly have an alginate content (expressed as alginic acid) in the range 2 to 11 percent by weight. The gels may be prepared by treating a water-insoluble or water-swellable alginate fiber, for example calcium alginate fiber, with an aqueous solution of a solubilizing salt, for example sodium chloride. The new gels are easier to handle than known alginate gels and are useful in wound dressing applications.
    Type: Grant
    Filed: September 7, 1993
    Date of Patent: January 9, 1996
    Assignee: Courtaulds Fibres (Holdings) Limited
    Inventor: Joseph Thompson
  • Patent number: 5466461
    Abstract: New polysaccharide esters are disclosed, and more precisely esters of acidic polysaccharides chosen from the group formed by carboxymethylcellulose, carboxymethyl starch and carboxymethylchitin. These new esters and some esters of the type already known are useful as medicaments, for the manufacture of pharmaceutical and cosmetic preparations, in the field of biodegradable plastic materials and, therefore, for the manufacture of medical, surgical and sanitary articles, as well as numerous other industrial sectors in the place of acidic polysaccharides now in common use.
    Type: Grant
    Filed: April 2, 1992
    Date of Patent: November 14, 1995
    Assignee: Fidia, S.p.A.
    Inventors: Francesco della Valle, Aurelio Romeo
  • Patent number: 5466457
    Abstract: A uniform lipstick molded of a composition by weight consisting of 0.5 to 50% beeswax, 0.5 to 50% of at least one ester of a saturated carboxylic acid and a saturated alcohol, the acid having 10-19 carbon atoms and the alcohol 14-40 carbon atoms, or the acid having 20-40 carbon atoms and the alcohol having 35-40 carbon atoms, 0.1 to 20% of water, and optionally other lipids and customary auxiliaries and additives, the composition being substantially free of mineral fatty components and paraffins.
    Type: Grant
    Filed: February 28, 1994
    Date of Patent: November 14, 1995
    Assignee: Beiersdorf Aktiengesellschaft
    Inventors: Gunther Schneider, Manfred Klier, Marta Aul, Stephan Teichmann
  • Patent number: 5461042
    Abstract: The present invention provides an improved compositions and methods for regulating the immune response, for ameliorating effects of stress, and for avoiding untoward effects of chemotherapy or exposure to irradiation by administration of androstenediol (AED) and androstenetriol (AET). The improved means of regulating immune response can be utilized in treating infectious diseases and immune diseases such as diabetes and chronic fatigue syndrome, both diseases now considered to be immune response related syndromes.
    Type: Grant
    Filed: January 3, 1994
    Date of Patent: October 24, 1995
    Inventor: Roger M. Loria
  • Patent number: 5447725
    Abstract: Methods for aiding periodontal tissue regeneration with compositions containing bioresorbable polymers, leachable solvents, and bioavailable drug actives. The compositions useful for these methods are characterized by becoming harder upon contact with the periodontal tissue such that the composition is effective for aiding tissue regeneration and by releasing a therapeutically-effective amount of drug active agent.
    Type: Grant
    Filed: June 11, 1993
    Date of Patent: September 5, 1995
    Assignee: The Procter & Gamble Company
    Inventors: Nalinkant C. Damani, Douglas C. Mohl, Robert E. Singer, Jr.
  • Patent number: 5399361
    Abstract: Collagen-containing sponges comprising an absorbable gelatin sponge, collagen, and an active ingredient are disclosed as are methods of enhancing wound healing of external and internal wounds using such sponges.
    Type: Grant
    Filed: June 28, 1994
    Date of Patent: March 21, 1995
    Assignee: Amgen Inc.
    Inventors: Suk-Zu Song, Andrew Morawiecki
  • Patent number: 5393528
    Abstract: A dissolvable element containing an agent material is used for local administration of the agent material in an internal body area. The dissolvable element is made of dissolvable polymer material and/or complex carbohydrate material which are food grade materials and have selected dissolving properties, such that it remains in substantially solid form before use, and dissolves due to human body temperatures and moisture during use to release the agent material in a desired timed release and dosage. As a contraceptive, the dissolvable element is preferably a film made of polyvinyl alcohol, polyethylene oxide, hydroxypropyl methyl cellulose and/or carboxymethyl cellulose. The dissolvable element may be formed as a laminate of different film layers for compound release properties, or it may be ground into particles and incorporated in a tampon or suppository. The dissolvable element may be foamed as a means for increasing its dissolution rate.
    Type: Grant
    Filed: June 1, 1993
    Date of Patent: February 28, 1995
    Inventor: Robert J. Staab
  • Patent number: 5385738
    Abstract: The present invention relates to a sustained-release injection, which comprises a suspension of a powder comprising an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, polysaccharides and synthetic high molecular compounds, preferably collagen, atelocollagen, gelatin, and a mixture thereof) in a viscous solvent for injection (e.g. vegetable oils, polyethylene glycol, propylene glycol, silicone oil, and medium-chain fatty acid triglycerides). The sustained-release injection can release the active ingredient at an effective level for a long period of time when injected.
    Type: Grant
    Filed: March 4, 1992
    Date of Patent: January 31, 1995
    Assignee: Sumitomo Pharmaceuticals Company, Ltd.
    Inventors: Yoshiya Yamahira, Keiji Fujioka, Shigeji Sato, Yoshihiro Takada